Clinical trials: Diffuse Systemic Sclerosis
Scleroderma
Brain Boost Program to Improve Cognitive Function in People With Systemic Sclerosis
The purpose of this study is to examine whether an 8-week online educational group-based program tailored to people with systemic sclerosis can help improve cognitive function and well-being.
- Trial name
- NCT06880627
- Testing
- Brain Boost group, Waitlist group
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Michigan
Scleroderma, Systemic, Sleep Apnea, Obstructive
Obstructive Sleep Apnea in Scleroderma and Pulmonary Involvement
Scleroderma is an autoimmune disease with skin manifestations and may have pulmonary involvement. Obstructive sleep apnea (OSA) may also be seen in scleroderma.
- Conditions
- Scleroderma, Systemic, Sleep Apnea, Obstructive, Pulmonary Disease
- Trial name
- OSASPI (NCT02740569)
- Testing
- No intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people
- Sponsor
- Marmara University
Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD).
- Trial name
- BLISSc-ILD (NCT05878717)
- Testing
- Belimumab
- Where
- 134 sites in United States, Argentina and 16 more
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Scleroderma
Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma
The purpose of this study is to investigate the effectiveness and safety of the drug Gleevec (imatinib) as a new treatment for patients with active diffuse scleroderma.
- Trial name
- NCT01545427
- Testing
- Imatinib mesylate
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Scleroderma
Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis
Organs of the gastrointestinal tract include the mouth, throat, stomach, intestines, and anus. Patients with scleroderma often have GIT disorders. GIT disorders can be severely debilitating and even life-threatening.
- Trial name
- PRISS (NCT01497743)
- Testing
- Lactobacillus
- Sponsor
- University of Michigan
Systemic Sclerosis
Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
This is a 48 week, phase IIa, single center, randomized, double-blind, placebo-controlled, proof-of-concept pilot study. All participants will first be treated with mycophenolate mofetil (MMF, Cellcept) and titrated up to a dose…
- Trial name
- NCT01670565
- Testing
- Belimumab, Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Hospital for Special Surgery, New York
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma
A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon
The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX0503) to relieve Raynaud's symptoms and increase blood flow to the fingers.
- Conditions
- Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Other Autoimmune Disease
- Trial name
- NCT00577304
- Testing
- Nitroglycerin, Topical AmphiMatrix
- Where
- 17 sites in United States
- Volunteers
- 200 people
- Sponsor
- MediQuest Therapeutics
Scleroderma, Pulmonary Hypertension
Endothelial Biomarkers of Systemic Sclerosis-associated Pulmonary Hypertension
Systemic sclerosis (SSc, AKA scleroderma) is an autoimmune condition characterized by endothelial damage and progressive fibrosis of the skin and internal organs.
- Trial name
- BOSS-PH (NCT03459716)
- Testing
- No intervention
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Systemic Sclerosis
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Primary Objective: To evaluate safety and tolerability of 8-week oral administration of SAR100842 in patients with diffuse cutaneous systemic sclerosis.
- Trial name
- NCT01651143
- Testing
- SAR100842
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 32 people
- Sponsor
- Sanofi
Scleroderma, Gastroparesis
Transcutaneous Electroacupuncture for Gastric Complications of Scleroderma
An innovative method of needleless transcutaneous electroacupuncture (TEA) using a newly developed watch-size stimulator is proposed.
- Trial name
- NCT03294616
- Testing
- transcutaneous electroacupuncture
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Scleroderma, Diffuse, Scleroderma, Systemic
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary…
- Conditions
- Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic
- Trial name
- NCT02682511
- Testing
- Oral Ifetroban
- Where
- 13 sites in United States, India
- Volunteers
- 34 people
- Sponsor
- Cumberland Pharmaceuticals
Systemic Sclerosis (Scleroderma)
Treatment of Early Systemic Sclerosis by Bosentan
Systemic sclerosis (ssc) is characterised by extensive tissue fibrosis. Using drugs that are capable of inhibiting fibroblast activity may be beneficial if administrered early in the disease course.
- Trial name
- TRANOS (NCT00226889)
- Testing
- bosentan
- Where
- Norway
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Rikshospitalet University Hospital
Primary Gougerot-Sjögren Syndrome, Systemic Sclerosis, Diffuse
Quantification and Characterization of Circulating Epithelial and Endothelial Cells in Gougerot-Sjögren Syndrome, Compared to Systemic Sclerosis
Primary Gougerot-Sjögren's syndrome is a systemic autoimmune disease belonging to the group of connectivities, whose physiopathology remains largely unknown.
- Trial name
- CIRCEE (NCT05528809)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Montpellier
Scleroderma, Interstitial Lung Disease
Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma
This study evaluates if dabigatran etexilate is safe for use in patients with Scleroderma and Interstitial Lung Disease. All patients will receive 75mg of dabigatran etexilate twice a day for 6 months.
- Trial name
- NCT02426229
- Testing
- dabigatran etexilate
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Medical University of South Carolina
Scleroderma, Scleroderma (Limited and Diffuse)
Personalized Online Occupational Therapy Intervention for Adults With Scleroderma
This pilot exploratory randomized controlled trial will evaluate the feasibility, acceptability, and safety of a personalized online occupational therapy intervention for adults with scleroderma in Spain.
- Conditions
- Scleroderma, Scleroderma (Limited and Diffuse), Systemic Sclerosis (SSc)
- Trial name
- NCT07661836
- Testing
- Personalized Online Occupational Therapy Intervention, Usual Care
- Where
- Spain
- Volunteers
- 24 people
- Sponsor
- Universidad de Zaragoza
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Scleroderma
Self-management Telehealth Program for Scleroderma
Scleroderma causes the skin on the hands to harden, causing the hands to contract, and the fingers to bend abnormally, which affect the patient's work and quality of life.
- Trial name
- NCT06990386
- Testing
- self-management program, Video guide and usual education, Telephone notification, video guide and usual education
- Where
- Thailand
- Volunteers
- 72 people
- Sponsor
- Khon Kaen University
Scleroderma, Systemic
Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
Progressive systemic sclerosis (SSc) is an immune-based disease that causes abnormal connective tissue growth of the skin and internal organs. At this point, there are no effective therapies for treating SSc.
- Trial name
- NCT00418132
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Scars, Scleroderma
Laser Treatment for the Improvement of Scars and Scleroderma
In this study, the investigators seek to evaluate the effects of a laser treatment on the redistribution/regeneration of collagen on the clinical, microscopic, and molecular profiles of hypertrophic scars and scleroderma.
- Trial name
- NCT04567537
- Testing
- Laser Treatment
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Scleroderma Systemic
Effect of the Use of Specific Oral Hygiene Devices on Gingival Health Among Patients With Systemic Sclerosis
Systemic sclerosis is a rare multisystem connective-tissue disorder characterized by three major pathological hallmarks: widespread fibrosis, vasculopathy and immunological abnormalities.
- Trial name
- ScleroBross (NCT04627857)
- Testing
- Manual toothbrush, Manual toothbrush and water flosser (Philips Sonicare AirFloss), Sonic toothbrush
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Strasbourg, France